U.S. markets close in 2 hours 2 minutes
  • S&P 500

    4,267.28
    +25.44 (+0.60%)
     
  • Dow 30

    34,217.96
    +343.72 (+1.01%)
     
  • Nasdaq

    14,356.14
    +84.41 (+0.59%)
     
  • Russell 2000

    2,324.94
    +21.47 (+0.93%)
     
  • Crude Oil

    73.12
    +0.04 (+0.05%)
     
  • Gold

    1,775.60
    -7.80 (-0.44%)
     
  • Silver

    26.02
    -0.09 (-0.35%)
     
  • EUR/USD

    1.1932
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.4970
    +0.0100 (+0.67%)
     
  • GBP/USD

    1.3920
    -0.0044 (-0.31%)
     
  • USD/JPY

    110.8850
    -0.0770 (-0.07%)
     
  • BTC-USD

    34,788.60
    +1,132.55 (+3.37%)
     
  • CMC Crypto 200

    837.71
    +51.10 (+6.50%)
     
  • FTSE 100

    7,109.97
    +35.91 (+0.51%)
     
  • Nikkei 225

    28,875.23
    +0.34 (+0.00%)
     

Regenxbio's Hunter Syndrome Gene Therapy Shows Efficacy Signals, Cognitive Development Up To Two Years

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Regenxbio Inc (NASDAQ: RGNX) has announced a safety update and additional positive interim data from its ongoing Phase 1/2 trial of RGX-121 to treat patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II (MPS II), also known as Hunter Syndrome.

  • The data will be presented at the American Society of Gene and Cell Therapy 24th Annual Meeting.

  • Heparan sulfate (HS) levels are a key biomarker of I2S enzyme activity. The patients in Cohorts 1 and 2 demonstrated decreased HS in the cerebrospinal fluid (CSF) for up to 2 years following one-time administration of RGX-121.

  • Combined median reductions from baseline were 30.3% at Week 8 and 35.0% at the last time point available for each patient.

  • These patients also demonstrated decreased levels of D2S6, a component of HS, up to 2 years, with median reductions of 44.1% at Week 8 and 40.4% at the last timepoint available for each patient.

  • Continuous neurocognitive development was observed up to two years after RGX-121 administration.

  • Five patients have assessments of neurodevelopment function at time points beyond six months, and of those patients, four have continued to demonstrate neurocognitive development.

  • Two patients in Cohort 1 discontinued enzyme replacement therapy (ERT) over one year after administration of RGX-121.

  • RGX-121 is an investigational one-time gene therapy designed to deliver the gene that encodes the iduronate-2-sulfatase (I2S) enzyme using the AAV9 vector. It is administered directly to the central nervous system.

  • Price Action: RGNX shares are up 3.19% at 36.42 during the market session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.